Chinese thoracic surgery experts consensus on postoperative follow-up plans for non-small cell lung cancer patients
- VernacularTitle:非小细胞肺癌术后随访中国胸外科专家共识
- Author:
Lunxu LIU
1
;
Shugeng GAO
2
;
Jianxing HE
3
;
Jian HU
4
;
Di GE
5
;
Hecheng LI
6
;
Mingqiang KANG
7
;
Fengwei TAN
2
;
Kaican CAI
8
Author Information
1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China
2. Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, P.R.China
3. Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, P.R.China
4. Department of General Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, P.R.China
5. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China
6. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P.R.China
7. Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, P.R.China
8. Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P.R.China
- Collective Name:Chinese Association of Thoracic Surgeons, Thoracic Surgery Society of China Medicine Education Association
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
postoperative follow-up;
thoracic surgery;
expert consensus
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(01):4-10
- CountryChina
- Language:Chinese
-
Abstract:
Resection is crucial for treating non-small cell lung cancer. Routine follow-up after surgery is an effective method for early detection and treatment of tumor recurrence and metastasis or the second primary tumor, which can improve the quality of life of patients and their prognosis. This consensus aims to provide a reference for colleagues responsible for postoperative follow-up of non-small cell lung cancer patients in China, and further improve the standardization of lung cancer diagnosis and treatment.